

VRL/SEC/BSE/91

August 22, 2012

Dept. of Corporate Services The Stock Exchange, Mumbai 25<sup>th</sup> Floor ,Phiroze Jeejeebhoy Towers Dalal Street, Mumbai

Sub.: Venus launches TRIOS, a miracle nano-emulsion for arthritic Pain

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has launched for the first time a research based product "TROIS" in the Indian markets. This patent protected topical nano-emulsion is developed by using the integrated natural medicine approach to relieve from all kind of arthritic pain.

The problem of Arthritis is a constantly growing epidemic in India. As per the latest reports, almost 15% of the Indian population is suffering with this crippling disease. Venus felt the pressing need to develop an alternative solution for rheumatic disorders and related infections, thus have come up for the first time with a topical nano emulsion "TROIS" to relieve the Arthritic pain. At present, there are many biological products available in the markets for treating arthritis and related condition, but they have many side effects associated with them.

Prevalent freatment of Rheumatoid diseases includes drugs such as non-steroidal, anti-inflammatory drugs (NSAIDS), corticosteroids, slow acting anti-rheumatic drugs (SAARDS) or disease modifying (DM) drugs include penicillin amine like drugs such as cyclophosphamide, methotrexate, gold salts, azothioprine, levamisole and the like. All these drugs have severe side effects and most of them are cytotoxic.

Trois is the most effective drug for the treatment of Arthritis and is getting outstanding response in the various markets across India. With the kind of response the company is getting for this revolutionary nano tech emulsion in pain management as topical pain killer in arthritis. Venus is hopeful of capturing a significant share of the rheumatoid arthritis drug market in India, which is speculated to grow up to \$672 million in 2013. Trois has been awarded gold medal in 2011, under India Innovation Growth Program, organized by FICCI, Lockheed Martin and IC2 Institute. Texas, We have already filed patents for TROIS in the major markets across the globe and based on the regulatory approvals, we are soon going the launch our products in the international markets as well.

Trois is indicated for the treatment of Pain & Inflammation as associated with Osteoarthritis. Rheumatoid arthritis, Juvenile idiopathic arthritis, Gouty arthritis, Ankylosing spondylitis, Psoriatic arthritis, Backache, Sprain and fibromyalgia.

Yours faithfully,

for VENUS REMEDIES LIMITED.

Ramanjit Kaur Assistant Manager

Corporate Communication

## **VENUS REMEDIES LIMITED**

Corporate Office: 51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India

Regd. Office: SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra, Chandigarh (U.T.) 160101, India

Website: www.venusremedies.com www.venusmedicineresearchcentre.com







Unit-1: 51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India Tel.: +91-172-3933094, 3933090, 2565577, Fax: +91-172-2565566 Unit-II:

Hill Top Industrial Estate, Jharmajri EPIP, Phase-J, (Extn.), Bhatoli Kalan, Baddi (H.P.) 173205, India Tel.: +91-1795-302100, 302101, 302107, Fax: +91-1795-271272

Unit-V: VENUS PHARMA GmbH AM Bahnhof I-3, D-59368, Werne, Germany